SGLT2 inhibitors have revolutionized diabetes treatment by targeting glucose reabsorption in the kidneys, effectively lowering blood sugar levels while offering additional cardiovascular and renal benefits. The gene discussed is SLC5A2; the disease is diabetes mellitus.